Related Experiment Video

Updated: Apr 13, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

16.5K

Lipid management in human immunodeficiency virus

Merle Myerson1

  • 1Cardiovascular Disease Prevention Program & Lipid Clinic, Cardiology Section, Institute for Advanced Medicine (HIV), Mount Sinai St. Luke's, Mount Sinai Roosevelt, 1111 Amsterdam Avenue, New York, NY 10025, USA.

Cardiology Clinics
|May 6, 2015
PubMed

Insights

Antiretroviral therapy has transformed human immunodeficiency virus (HIV) infection into a manageable condition. This review discusses applying general guidelines to HIV patients and identifies knowledge gaps in managing dyslipidemia.

Area of Science:

  • Internal Medicine
  • Infectious Diseases
  • Cardiology

Background:

  • Antiretroviral medications have shifted human immunodeficiency virus (HIV) from a fatal illness to a chronic, manageable condition.
  • Dyslipidemia is a common comorbidity in patients with HIV, increasing cardiovascular risk.
  • Existing guidelines for dyslipidemia management are primarily based on the general population.

Purpose of the Study:

  • To review current recommendations for dyslipidemia management in the general population.
  • To suggest how these recommendations can be applied to patients living with HIV.
  • To identify gaps in knowledge regarding the diagnosis and management of dyslipidemia in the context of HIV.

Main Methods:

  • Literature review of current dyslipidemia guidelines.
  • Analysis of existing data on dyslipidemia in HIV-infected individuals.
  • Identification of areas lacking sufficient research for HIV patient populations.

Main Results:

  • General dyslipidemia guidelines can be adapted for HIV patients, but require careful consideration of HIV-specific factors.
  • Significant knowledge gaps exist regarding optimal diagnostic and management strategies for dyslipidemia in patients with HIV.
  • Further research is needed to address the unique challenges of managing dyslipidemia in this population.

Conclusions:

  • While antiretroviral therapy has improved outcomes for HIV patients, managing associated metabolic complications like dyslipidemia remains a challenge.
  • Tailored approaches and further research are crucial for effectively addressing dyslipidemia in individuals living with HIV.
  • Addressing these knowledge gaps is essential for improving long-term cardiovascular health in the growing population of HIV survivors.

Keywords:
Antiretroviral therapyCardiovascular risk factorsDyslipidemiaHIVInfectious diseases

More Related Videos

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models09:54

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

10.8K
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

3.0K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
602
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
1.7K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.4K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
35